Pharmaceutical News

RSS

Abiraterone acetate confirmed to offer significant survival benefit to advanced prostate cancer patients

Results of a phase 3 trial published in The Lancet Oncology have confirmed that the drug abiraterone acetate (marketed as Zytiga®) offers a significant survival benefit to patients with castration-resistant prostate cancer, which is spreading to other parts of their body (known as metastatic prostate cancer).

18 Sep 2012

Power of taxane-based chemotherapy drugs may be potentially underestimated

The power of taxane-based chemotherapy drugs are misunderstood and potentially underestimated, according to researchers at Weill Cornell Medical College in the September 15 issue of the journal Cancer Research.

18 Sep 2012

Study finds major reason why melanoma is largely resistant to chemotherapy

Researchers with UC Irvine's Chao Family Comprehensive Cancer Center have identified a major reason why melanoma is largely resistant to chemotherapy.

18 Sep 2012

Vitamin E may prevent cancer in patients with Cowden Syndrome

Cleveland Clinic researchers have discovered that vitamin E may prevent cancer in patients with an under-recognized genetic disorder.

18 Sep 2012

Hemerus Medical’s SOLX red blood cell additive receives world's first CE Marking

Hemerus Medical, LLC, a Minnesota-based company that develops innovative technologies for the collection, processing, preservation, and storage of blood products announced that it has received the world's first CE Marking for a 56 day red blood cell storage solution – the SOLX red blood cell additive (AS-7).

18 Sep 2012

Wockhardt receives FDA marketing approval for Lansoprazole

Pharmaceutical and biotechnology major Wockhardt has received final approval from the United States Food & Drug Administration (US FDA) for marketing 15mg and 30 mg delayed release capsules of Lansoprazole, which is used in treatment of peptic ulcers. Lansoprazole is the generic name for the brand Prevacid, marketed in the United States by Takeda. Wockhardt is launching the product immediately.

17 Sep 2012

FDA designates Rib-X's delafloxacin as QIDP for acute bacterial skin and skin structure infections

Rib-X Pharmaceuticals, Inc., today announced that the Food and Drug Administration (FDA) designated delafloxacin as a Qualified Infectious Disease Product (QIDP) for the indications of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).

17 Sep 2012

Limited positive effect of Tafamidis in neurological disorders

Tafamidis meglumine was approved in November 2011 for the treatment of transthyretin amyloidosis in adults.

17 Sep 2012

Risks of antidiabetic drug substantially overrated for patients with reduced kidney function

The antidiabetic drug metformin is not prescribed for patients with reduced kidney function because the risk of adverse effects has been regarded as unacceptably high. A study at Sahlgrenska Academy, University of Gothenburg, Sweden, has found that the risks have been substantially overrated. As a result, many more patients with diabetes may be able to enjoy the benefits of the medication.

17 Sep 2012

Progenra’s P5091 inhibits growth of bortezomib resistant multiple myeloma tumor cells

Researchers at the Dana-Farber Cancer Institute and Progenra, Inc. announce the publication of a research article entitled "A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance."

17 Sep 2012

PARP inhibitors may be novel treatment strategy in women with HER2-positive breast cancers

Poly (ADP-Ribose) polymerase (PARP) inhibitors, shown to have clinical activity when used alone in women with familial breast and ovarian cancers linked to BRCA mutations, may be a novel treatment strategy in women with HER2-positive breast cancers, according to the results of a study published in Cancer Research, a journal of the American Association for Cancer Research.

17 Sep 2012

Study could reveal whether breast cancer patients with BRCA mutations are responsive to Veliparib

Ongoing research at the Methodist Cancer Center could reveal whether metastatic breast cancer patients with BRCA gene mutations are particularly responsive to a drug regimen that includes Veliparib, an investigational drug believed to hamper cancer cells.

15 Sep 2012

MIT engineers use ultrasound waves to enhance permeability of skin to drugs

Using ultrasound waves, MIT engineers have found a way to enhance the permeability of skin to drugs, making transdermal drug delivery more efficient. This technology could pave the way for noninvasive drug delivery or needle-free vaccinations, according to the researchers.

15 Sep 2012

U.K. scientists develop new test to catch drugs-cheats in sport

Scientists from three UK universities have developed a new test to catch drugs-cheats in sport.

15 Sep 2012

FDA approves Lannett’s ANDA for Butalbital, Acetaminophen and Caffeine Tablets

Lannett Company, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Butalbital, Acetaminophen and Caffeine Tablets, USP, 50mg/325mg/40mg.

15 Sep 2012

Experimental diabetes drug shows promise against Alzheimer's

A drug designed for diabetes sufferers could have the potential to treat neurodegenerative diseases like Alzheimer's, a study by scientists at the University of Ulster has revealed.

15 Sep 2012

Levitation can improve drug development process

It's not a magic trick and it's not sleight of hand - scientists really are using levitation to improve the drug development process, eventually yielding more effective pharmaceuticals with fewer side effects.

14 Sep 2012

Insufficient evidence to support effectiveness of black cohosh for menopausal symptoms

Although many women coping with hot flashes and other distressing symptoms of menopause have turned to black cohosh supplements as a treatment alternative, a new review by The Cochrane Library finds no evidence that the herb is effective.

14 Sep 2012

IU chemists develop fully synthetic artemisinin to help reduce cost of live-saving drugs

In 2010 malaria caused an estimated 665,000 deaths, mostly among African children. Now, chemists at Indiana University have developed a new synthesis for the world's most useful antimalarial drug, artemisinin, giving hope that fully synthetic artemisinin might help reduce the cost of the live-saving drug in the future.

14 Sep 2012

Study: 172K polymorphism makes certain forms of HIV less resistant to drugs

The human immunodeficiency virus (HIV) can contain dozens of different mutations, called polymorphisms. In a recent study an international team of researchers, including MU scientists, found that one of those mutations, called 172K, made certain forms of the virus more susceptible to treatment. Soon, doctors will be able to use this knowledge to improve the drug regiment they prescribe to HIV-infected individuals.

14 Sep 2012

Pharmaceutical News

Abiraterone acetate confirmed to offer significant survival benefit to advanced prostate cancer patients

Power of taxane-based chemotherapy drugs may be potentially underestimated

Study finds major reason why melanoma is largely resistant to chemotherapy

Vitamin E may prevent cancer in patients with Cowden Syndrome

Hemerus Medical’s SOLX red blood cell additive receives world's first CE Marking

Wockhardt receives FDA marketing approval for Lansoprazole

FDA designates Rib-X's delafloxacin as QIDP for acute bacterial skin and skin structure infections

Limited positive effect of Tafamidis in neurological disorders

Risks of antidiabetic drug substantially overrated for patients with reduced kidney function

Progenra’s P5091 inhibits growth of bortezomib resistant multiple myeloma tumor cells

PARP inhibitors may be novel treatment strategy in women with HER2-positive breast cancers

Study could reveal whether breast cancer patients with BRCA mutations are responsive to Veliparib

MIT engineers use ultrasound waves to enhance permeability of skin to drugs

U.K. scientists develop new test to catch drugs-cheats in sport

FDA approves Lannett’s ANDA for Butalbital, Acetaminophen and Caffeine Tablets

Experimental diabetes drug shows promise against Alzheimer's

Levitation can improve drug development process

Insufficient evidence to support effectiveness of black cohosh for menopausal symptoms

IU chemists develop fully synthetic artemisinin to help reduce cost of live-saving drugs

Study: 172K polymorphism makes certain forms of HIV less resistant to drugs

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Latest News